Determinants of quality of life in acute heart failure patients with and without comorbidities: a prospective, observational study

Jan C. van den Berge 1*, Laura C. van Vark 1, Douwe Postmus 2, Elisabeth M.W.J. Utens 3,4, Hans L. Hillege 2, Eric Boersma 1, Ivonne Lesman-Leegte 2, and K. Martijn Akkerhuis 1

1Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam 3015 GD, the Netherlands; 2Department of Epidemiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, the Netherlands; 3Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC—Sophia Children’s Hospital, University Medical Center Rotterdam, Wytemaweg 8, Rotterdam 3015 CN, the Netherlands; and 4Academic Center for Child Psychiatry the Bascule/Department of Child and Adolescent Psychiatry, Academic Medical Center, Meibergdreef 5, Amsterdam, 1105 AZ, The Netherlands

Received 6 February 2021; revised 24 June 2021; editorial decision 28 June 2021; accepted 28 June 2021

Aims

The relation between non-cardiac comorbidities and health-related quality of life (HRQoL) in patients with heart failure (HF) has been studied to a limited extent. To investigate the HRQoL and their determinants among HF patients with and without comorbidities.

Methods and results

TRIUMPH (TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure) is a Dutch prospective, multicentre study enrolling 496 acute HF patients between 2009 and 2014. We included 334 patients who had completed the HRQoL questionnaires at baseline. The HRQoL was measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQuality-of-life five Dimensions (EQ-5D). Comorbidity was defined as having a history of at least one of the following comorbidities: chronic kidney disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD), and/or cerebrovascular accident. Patients with comorbidity (n = 205, 61%) had lower scores on the physical limitation scale and clinical summary score of the KCCQ (P = 0.03 and P = 0.01, respectively). Female sex, COPD, previous HF, increasing body mass index (BMI), elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), high systolic blood pressure, and the presence of anxiety and/or depression negatively influenced the HRQoL among HF patients with comorbidity. Besides anxiety and depression, we hardly found any other determinant of HRQoL in patients without comorbidity.

Conclusion

Heart failure patients without comorbidity had better HRQoL than patients with comorbidity. Sex, previous HF, BMI, COPD, systolic blood pressure, NT-proBNP levels, and also anxiety and depression were determinants of HRQoL in patients with comorbidity. In those without comorbidity, apart from anxiety and depression, no further determinants of HRQoL were found.

Keywords

Comorbidity • Health-related quality of life • Heart failure

Implication for practice

• Heart failure (HF) patients value health-related quality of life (HRQoL) at least as relevant as longevity
• HRQoL should get more attention among clinicians
• Optimal HF treatment is important to improve HRQoL
• Optimal treatment of comorbidities may improve HRQoL

* Corresponding author. Tel: +31 10 703 4479, Fax: +31 10 704 4759, Email: j.vandenberge@erasmusmc.nl
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Introduction**

Heart failure (HF) is a clinical syndrome that is frequently accompanied by non-cardiac comorbidities such as renal dysfunction, chronic obstructive pulmonary disease (COPD), diabetes, cerebrovascular accident (CVA), and anaemia. Some of these comorbidities may be a result of HF, whereas other diseases may be associated with the development of HF.\(^1^,^2\)

It has also been established that among patients with HF, those with one or more comorbidities have a worse prognosis when compared with those without comorbidities.\(^3\) Besides a poor prognosis, HF patients also have an impaired health-related quality of life (HRQoL).\(^5\) The HRQoL among patients with HF has not only been found to be worse than that in the general population, but it is even worse than that of patients with other chronic conditions.\(^4^,^5\) Moreover, an impaired HRQoL is a driver of adverse outcomes in HF.\(^6\) Also from a patient’s perspective, HRQoL is very important. Some studies have found that patients value the quality of life at least as important as longevity.\(^7^,^8\) Therefore, HRQoL is an interesting and important topic from a clinical and research perspective.

The relation between non-cardiac comorbidities and HRQoL in patients with HF has been studied to a limited extent. The relative few studies available have shown a relation between comorbidities and HRQoL,\(^9^,^10\) but there is inconsistency among the different studies.\(^12\) However, there have been no studies reporting on differences in determinants of HRQoL between patients with and without (multi-)comorbidity. Therefore, we aimed to investigate the HRQoL and their determinants among HF patients with and without somatic comorbidities based on data from the TRIUMPH study [TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure (TRIUMPH): NTR1893].

**Methods**

**Study population and procedures**

The design of the TRIUMPH study has been described previously.\(^13^,^14\) In short, this study is a prospective, observational study performed in 14 hospitals in the Netherlands. In the period of September 2009 until December 2013, patients aged 18 years and older hospitalized with acute HF were enrolled. Acute HF was defined as either new-onset HF or worsening symptoms of chronic HF. We included patients admitted with acute HF with evidence of sustained systolic diastolic dysfunction. Additionally, patients were included if their natriuretic peptide level should be at least three times higher than the upper limit of normal and they should be treated with intravenous diuretics during the hospitalization. We obtained written informed consent from all patients. All participating centre’s ethical committees have given approval for the study. The investigation conforms with the principles outlined in the Declaration of Helsinki.\(^15^,^16\)

The primary aim of the TRIUMPH study was to investigate the clinical value of repeated measurements of several biomarkers in patients with acute HF. One of the secondary aims was to study HRQoL in patients with acute HF.

During hospitalization, patients were visited three times: at admission, at Days 2–4 following admission and on the day of discharge. After hospital discharge, four follow-up moments were planned: at 2–4 weeks, 3 months, 6 months, and 9–12 months. At each measurement moment, patients underwent physical examination (including blood pressure, heart rate, and weight measurement), blood sampling, and patients were scored according to the New York Heart Association (NYHA) classification. Patients were treated in accordance with the European Society of Cardiology Guidelines\(^14\) by their treating physician. The TRIUMPH study did not intervene in the usual care.

**Quality of life measurement**

Patients were asked to complete several questionnaires before hospital discharge and at the last follow-up visit. HRQoL was measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) or EuroQuality-of-life 5 Dimensions (EQ-5D). Symptoms of anxiety and depression were measured by the Hospital Anxiety and Depression Scale (HADS).

The KCCQ is a disease-specific questionnaire to measure the HRQoL of patients with HF. This 23-item questionnaire covers the following six domains: physical limitation (KCCQ-PL), symptom stability, total symptom score (combination of symptom frequency and symptom burden), self-efficacy score, quality of life score, and social limitation. Two summary scores can be computed from these domains: the clinical summary score (KCCQ-CS) comprising the domains physical limitation (KCCQ-PL), symptom stability, total symptom score, and the overall summary score (KCCQ-OS) which captures the domains physical limitation, total symptom score, quality of life, and social limitation. Each domain and summary score has been transformed into a 0–100 scale. Higher scores indicate better HRQoL.\(^17\)

The EQ-5D is a general, non-disease-specific HRQoL questionnaire that consists of two components. The first component is the health state description and the second component is the health state evaluation. We used the three-level version of the EQ-5D for the health state description. The three levels were: (i) no problems, (ii) some problems, and (iii) extreme problems. A total of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were scored according to these three levels. For each dimension, patients were asked to choose the statement which best described their health status that day. In the second part (i.e. health state evaluation) patients were asked to score their health status by using a visual analogue scale within a range of 0 (worst imaginable health status) to 100 (best imaginable health status).\(^18\)

The HADS has been shown a valid and reliable instrument to assess symptoms of anxiety and depression. Patients were asked to answer fourteen questions. Seven items contribute to each of the two subscales (anxiety and depression, respectively) and were answered on a 4-point Likert scale from 0 to 3, which implies a total score range per subscale of 0–21.\(^19^,^20\) A score of ≥8 points on the subscale anxiety as well as on the subscale depression was used to determine whether patients had an anxiety disorder and/or depression.\(^19\)

**Definitions**

To answer our research question, analyses were stratified by comorbidity. Comorbidity was defined as having a history of at least one of the following significant, non-cardiac comorbidities: chronic kidney disease, diabetes mellitus, COPD, and/or CVA. The presence of the comorbidities was according to the investigator’s statement of the medical history in the case report form. These four comorbidities were chosen because of their high prevalence in HF and because there is evidence that they may influence HRQoL and/or the presence of anxiety and depression.

Heart failure with reduced ejection fraction was defined as a left ventricular ejection fraction below 50%. During admission, NYHA classification was determined at three-time points. Since the NYHA classification at discharge was considered the most stable of these three, this measurement was used as the baseline NYHA classification.
Statistical analyses
Categorical variables are presented as numbers and percentages. The χ² test was used to compare categorical variables. Continuous variables are given as median with interquartile range (IQR) and were compared with the Mann–Whitney U test.

The determinants of HRQoL (based on the EQ-5D and KCCQ) were analysed by using linear regression models and logistic regression, respectively. First, we performed univariable analyses in the total study population with all baseline characteristics. Anxiety and depression were included as predictors, using the HADS model to define whether there was anxiety and/or depression or not. Then, all determinants with P < 0.2 in the univariable analyses were included in the multivariable analyses (forward step method) in order to search for determinants of HRQoL in the total population. Further, the significant (i.e. P < 0.05) determinants of HRQoL in the total population plus age and sex were included in the multivariable analyses (enter method) to test determinants of HRQoL in patients with and without comorbidity. Finally, we tested for interaction between comorbidity and the determinants of HRQoL.

All tests were two-tailed and P-values < 0.05 were considered statistically significant. We used SPSS software (SPSS 24.0, IBM Corp., Armonk, NY, USA) for all statistical analyses.

Results
Baseline characteristics
In total, 496 patients were enrolled in the TRIUMPH study. Three patients withdrew their informed consent. Another 18 patients were excluded from statistical analyses because of inclusion violation since they had no evidence of sustained systolic or diastolic dysfunction. Of the 475 remaining patients, we included the 334 patients (70%) who had completed the HRQoL questionnaires at baseline into the analyses set. Besides higher occurrence of comorbidity and higher levels of NT-proBNP, the baseline characteristics of the 141 patients (74%) with comorbidity who did not complete the HRQoL questionnaires were almost comparable with that of the patients in the analyses set (see Supplementary material online, Table S1).

The included patients consisted of 219 men (66%), the median age was 74 years (IQR 65–81) and 205 patients (61%) had at least one of the comorbidities diabetes mellitus, chronic kidney dysfunction, COPD, or prior CVA (Table 1). Almost half of the patients had ischaemic HF and 85% had HF with reduced ejection fraction.

On average, patients with comorbidity were 3 years older, more frequently male, and more often had a history of HF and an ischaemic cause of HF. Of the patients with comorbidity, 135 patients (65%) had only one of the four comorbidities and 14 patients (7%) had three or more. The most common comorbidity was diabetes mellitus. Notably, indicators of cardiac function like left ventricular ejection fraction, NT-proBNP, and NYHA class did not differ between patients with and without comorbidity.

Differences in health-related quality of life according to comorbidity
The NYHA classification at the discharge of patients with and without comorbidity was comparable (Table 2). Furthermore, the EQ-5D score neither did differ between patients with and without comorbidity (P = 0.16). In contrast, the HRQoL measured by the disease-specific questionnaire (i.e. KCCQ) showed that patients with comorbidity had a significant lower KCCQ-PL and KCCQ-CS (P = 0.03 and P = 0.01, respectively). Lastly, patients with comorbidity had more depressive symptoms than those without comorbidity (42% vs. 30%, P = 0.03).

A total of 154 of the 334 included patients (46%) also completed the HRQoL questionnaires after 9–12 months of follow-up. This response rate was comparable between patients with and without comorbidity (P = 0.43). After 1 year follow-up, the NYHA classification was worse in patients with comorbidity (Table 2). Both the generic (i.e. EQ-5D) and disease-specific (i.e. KCCQ) questionnaires measured a worse HRQoL in patients with comorbidity after 9–12 months of follow-up.

Determinants of health-related quality of life
The studied comorbidities (i.e. COPD, CVA, chronic kidney dysfunction, and diabetes mellitus) were found to be modest predictors of the HRQoL in the total study population. After multivariable adjustment, COPD was the only of these comorbidities that was found to be a significant determinant, namely for KCCQ-PL and KCCQ-CS (β = 10.439 (95% CI –18.721 to –2.157), β = 7.815 (95% CI –14.527 to 1.103), respectively, Table 3).

Besides the studied comorbidities, other factors were associated with HRQoL. Increasing age, female sex, increasing body mass index (BMI), and higher NT-proBNP were the major determinants of an adverse score on the KCCQ. Furthermore, depression (as measured with the HADS) was also associated with lower HRQoL scores, both on the EQ-5D (β = 0.244 (95% CI –0.314 to –0.174)) and on the KCCQ [PL: β = 15.179 (95% CI –21.841 to –0.8517); CS: β = 13.677 (95% CI –19.142 to –8.212); OS: –14.279 (95% CI –19.695 to –8.864)].

The determinants of HRQoL differed considerably between patients with and without comorbidity (Figure 1). Sex, previous HF, BMI, NT-proBNP, and systolic blood pressure at discharge were determinants of HRQoL among HF patients with comorbidity. The presence of anxiety and/or depression also negatively influenced the HRQoL of patients with and without comorbidity. Besides anxiety and depression, we hardly found any other determinant of HRQoL in patients without comorbidity.

Discussion
In this prospective, multi-centre study, we found that patients with one or more of the four investigated comorbidities (i.e. COPD, diabetes mellitus, chronic kidney disease, and/or prior CVA) had a higher prevalence of depression at baseline than patients without comorbidity. Of the four comorbidities, only COPD was modestly associated with worse HRQoL. Important determinants of HRQoL in our population were sex, history of HF, BMI, NT-proBNP at admission, systolic blood pressure at discharge, and the presence of a depression. Most of these characteristics were also associated with HRQoL in the subgroup of patients with comorbidity. In contrast, besides anxiety and depression, we hardly found any other determinant of HRQoL in patients without comorbidity.
Differences in health-related quality of life

To the best of our knowledge, this study is the first investigating differences in HRQoL between HF patients with and without a cluster of four selected non-cardiac comorbidities. Despite a comparable severity of HF (indicated by equal NT-proBNP levels and comparable NYHA classification) in patients with and without comorbidity, we found lower HRQoL and higher prevalence of depression in HF patients with comorbidity. A possible explanation of this might be that patients with comorbidity already had a worse HRQoL pre-admission. This potential lower HRQoL pre-admission may not only be due to the comorbidities for which was stratified in this study (i.e., prior CVA, chronic kidney dysfunction, diabetes, and COPD), but we also found other factors that may cause lower HRQoL in patient with comorbidity, like higher BMI, more frequent a history of HF before inclusion and hypertension.9

Question remains why there was a difference in HRQoL measured with the KCCQ questionnaire between patients with and without comorbidity and no difference in the EQ-5D score despite the fact that there is some overlap in the questions among both questionnaires.17,18 This inconsistency may be due to the fact that two questionnaires consist of different questions on different aspects of HRQoL and, hence, may give different outcomes. Further, the KCCQ questionnaire is disease-specific and the EQ-5D is short and very generic. On the other hand, we think that the difference in way of asking the questions may also be responsible for this difference. In the EQ-5D questionnaire, patients were asked about their functioning at that day.18 However, the KCCQ questionnaire specifically asked to complete the questions about their functioning and to compare it with their functioning 2 weeks ago.17 This explicitly stated 2-week time frame may cause that patients answer the questions in a different way.

### Table 1  
Baseline characteristics of patients with and without comorbidity

|                        | Overall sample | Comorbidity + | Comorbidity - | p-value |
|------------------------|----------------|---------------|---------------|---------|
|                        | n = 334        | n = 205       | n = 129       |         |
| Demographics           |                |               |               |         |
| Age years              | 74 (65–81)     | 76 (66–81)    | 73 (60–80)    | 0.04    |
| Male                   | 219 (66%)      | 145 (71%)     | 74 (57%)      | 0.01    |
| Caucasian              | 319 (96%)      | 196 (96%)     | 123 (95%)     | 0.59    |
| Medical history        |                |               |               |         |
| Previous heart failure | 215 (65%)      | 144 (71%)     | 71 (55%)      | 0.004   |
| Previous heart failure hospitalization within last 6 months | 69 (21%) | 49 (24%) | 20 (16%) | 0.06 |
| Ischaemic heart failure| 158 (47%)      | 115 (56%)     | 43 (33%)      | <0.001  |
| Heart failure with reduced ejection fraction | 228 (85%) | 134 (82%) | 94 (89%) | 0.15 |
| Hypertension           | 166 (50%)      | 119 (58%)     | 47 (36%)      | <0.001  |
| Atrial fibrillation    | 143 (43%)      | 94 (46%)      | 49 (38%)      | 0.16    |
| Diabetes mellitus      | 118 (35%)      | 118 (58%)     | 0 (0%)        | <0.001  |
| Chronic obstructive pulmonary disease | 65 (20%) | 65 (32%) | 0 (0%) | <0.001 |
| Chronic kidney dysfunction | 55 (17%) | 55 (27%) | 0 (0%) | <0.001 |
| Cerebrovascular accident | 52 (16%) | 52 (25%) | 0 (0%) | <0.001 |
| Baseline measurements   |                |               |               |         |
| Body mass index, kg/m² | 28 (25–31)     | 28 (25–32)    | 26 (24–30)    | 0.004   |
| Systolic blood pressure, mmHg | 125 (110–148) | 125 (110–148) | 124 (110–145) | 0.53 |
| Diastolic blood pressure, mmHg | 74 (64–85) | 70 (65–82) | 78 (64–89) | 0.049 |
| Heart rate, bpm         | 85 (72–100)    | 84 (70–99)    | 90 (76–105)   | 0.02    |
| Creatinin, μmol/L       | 122 (100–158)  | 134 (106–181) | 111 (95–140)  | <0.001  |
| NT-proBNP, pg/mL        | 3738 (1928–8601) | 3726 (1928–9381) | 3738 (2072–6816) | 0.79 |
| Left ventricular ejection fraction % | 30 (21–40) | 30 (22–42) | 30 (20–39) | 0.09 |
| NYHA classification     |                |               |               | 0.29    |
| I                      | 35 (13%)       | 20 (12%)      | 15 (14%)      |         |
| II                     | 127 (47%)      | 71 (43%)      | 56 (52%)      |         |
| III                    | 98 (36%)       | 65 (39%)      | 33 (31%)      |         |
| IV                     | 12 (4%)        | 9 (6%)        | 3 (3%)        |         |

Results depicted as median (interquartile range) or N (%).

NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.

Comorbidity defined as presence of one or more of the following: diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease and/or prior cerebrovascular accident.

P-value for comparison between patients with and those without comorbidity.
Determinants of health-related quality of life

A unique aim of this study was to investigate the determinants of HRQoL in patients with and without comorbidity. Female sex, previous HF, COPD, increasing BMI, and higher NT-proBNP levels at admission were found to be important determinants of worse HRQoL in patients with comorbidity. Those determinants were also associated with HRQoL in studies that did not investigate differences in determinants of HRQoL in patients with and without comorbidity.21,22 Furthermore, female patients, patients with a history of CVA and patients with worse NYHA classification at discharge were at higher risk for depression.

A striking finding was that we, apart from depression, hardly found any determinant of HRQoL in patients without comorbidity. A possible explanation for this might be that HF itself is by far the most important determinant of the reduced HRQoL in patients without comorbidity. Another possible explanation might be that there are other determinants of HRQoL in patients without comorbidity that we did not measure (e.g. patients’ illness knowledge, patients’ coping strategy,23 and socioeconomic status.24) Indeed, these determinants may also influence the HRQoL of patients with comorbidity but not only in those without comorbidity.

Besides the above-mentioned demographic and clinical factors, we also found psychosocial determinants of HRQoL: the presence of anxiety and depression negatively influenced HRQoL. This may have important clinical implications for both patients with and without comorbidity.

Clinical implication

Our opinion is that HRQoL should get more attention among clinicians. Prognosis should not be the only therapeutic goal. Since HF patients value HRQoL at least as important as longevity,25 clinicians should strive for better HRQoL instead of focusing on survival per se. Indeed, in our study, we only found a limited number of determinants of HRQoL that may be influenced by clinicians, although we think that optimal HF treatment in accordance with the guidelines is an important intervention for improving HRQoL.25 Also, optimal treatment of comorbidities like diabetes mellitus, chronic kidney disease, and COPD, and managing the risk factors BMI and systolic blood pressure may improve HRQoL. This is in line to what Lawson et al.9 recently stated based on data of the Swedish Heart Failure Registry, namely that in order to improve HRQoL, HF guideline-driven care needs to include optimal management of the most prevalent non-cardiovascular comorbidities. Furthermore, psychosocial interventions to intervene with depressive and anxiety symptoms may also break the vicious circle of anxiety/depression and HRQoL. The last, but very important and maybe a ‘bit forgotten’ intervention we would like to emphasize, is cardiac rehabilitation. Cardiac rehabilitation should at least consist of exercise therapy and patient education.25-27 Besides improving HRQoL, cardiac rehabilitation in patients with HF has proven to be favourable for other endpoints like rehospitalization and probably (long-term) mortality.28 Despite the proven effectiveness and the strong recommendations in the HF guidelines,26 the number of referrals to cardiac rehabilitation29 and patients’ adherence28 may be increased enormously.

Strengths and limitations

This study is the first reporting HRQoL and their determinants in HF patients with and without comorbidity. Moreover, we used a set of different questionnaires to get an impression of a patient’s QoL, namely EQ-5D, KCCQ, and HADS. However, some limitations should be mentioned. First, this study was designed as a sub-study of the TRIUMPH study. Therefore, results of this sub-study may be underpowered. Another limitation is that the choice for the comorbidities CVA, chronic kidney disease, COPD and diabetes was relatively arbitrary. Indeed, we have chosen common HF non-comorbidities that may influence HRQoL25 but others may have chosen other comorbidities. However, as there were no previous studies investigating this topic, we should make a selection. Finally, 70% of the initial study population completed the baseline questionnaires. Part of the patients who could not complete the questionnaires at discharge were those who died during admission. The other parts of the 30% non-responders were patients who have not

| Table 2 | HRQoL, anxiety, and depression in patient with and without comorbidity |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Comorbidity +   | Comorbidity -   | P-value         | Comorbidity +   | Comorbidity -   | P-value         |
| NYHA           |                 |                 |                 |                 |                 |                 |
| I              | 20 (12%)        | 15 (14%)        | 0.29            | 10 (12%)        | 23 (37%)        | 0.002           |
| II             | 71 (43%)        | 56 (52%)        |                 | 55 (65%)        | 24 (39%)        |                 |
| III            | 65 (39%)        | 33 (31%)        |                 | 19 (22%)        | 14 (23%)        |                 |
| IV             | 9 (6%)          | 3 (3%)          |                 | 1 (1%)          | 1 (2%)          |                 |
| EQ-SD          |                 |                 |                 |                 |                 |                 |
| EQ-SD score    | 0.68 (0.34–0.81)| 0.69 (0.43–0.86)| 0.16            | 0.81 (0.65–0.89)| 0.86 (0.77–1.00)| 0.04            |
| EQ-SD VAS      | 60 (49–70)      | 60 (50–70)      | 0.33            | 70 (55–80)      | 70 (60–80)      | 0.19            |
| KCCQ           |                 |                 |                 |                 |                 |                 |
| KCCQ-PL        | 33 (13–63)      | 42 (21–71)      | 0.03            | 58 (33–82)      | 75 (44–96)      | 0.01            |
| KCCQ-CS        | 31 (16–54)      | 35 (25–61)      | 0.01            | 69 (41–88)      | 77 (50–96)      | 0.05            |
| KCCQ-OS        | 30 (18–51)      | 35 (21–56)      | 0.14            | 65 (40–85)      | 77 (49–91)      | 0.06            |
| HADS            |                 |                 |                 |                 |                 |                 |
| Anxiety        | 63 (32%)        | 46 (36%)        | 0.41            | 17 (19%)        | 12 (20%)        | 0.8             |
| Depression     | 83 (42%)        | 38 (30%)        | 0.03            | 24 (26%)        | 10 (17%)        | 0.19            |

Results depicted as median (interquartile range) or N (%). CS, clinical summary score; EQ-5D, EuroQuality-of-life 5 Dimensions; HADS, Hospital Anxiety and Depression Scale; HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart Association; OS, overall summary score; PL, physical limitation; VAS, visual analogue scale.
Table 3  Multivariable adjusted determinants of HRQoL in the total population

|                      | $\beta$ | 95% CI lower bound | 95% CI upper bound |
|----------------------|---------|--------------------|--------------------|
| **EQ-5D score**      |         |                    |                    |
| Age (per 10 years increase) | -0.038  | -0.061             | -0.015             |
| Male                 | 0.109   | 0.046              | 0.172              |
| NYHA Class III/IV    | -0.081  | -0.143             | -0.02              |
| Anxiety              | -0.150  | -0.221             | -0.079             |
| Depression           | -0.244  | -0.314             | -0.174             |
| **EQ-SD VAS**        |         |                    |                    |
| Age (per 10 years increase) | -0.093  | -2.978             | 0.471              |
| Male                 | 3.820   | -0.868             | 8.508              |
| Previous HF          | -5.051  | -9.646             | -0.456             |
| LVEF (per % increase) | 0.252   | 0.095              | 0.409              |
| Anxiety              | -8.342  | -13.389            | -3.094             |
| Depression           | -5.803  | -10.963            | -0.644             |
| **KCCQ-PL**          |         |                    |                    |
| Age (per 10 years increase) | -0.382  | -2.939             | 2.175              |
| Male                 | 13.607  | 6.977              | 20.238             |
| Previous HF          | -9.090  | -15.686            | -2.494             |
| Chronic obstructive pulmonary disease | -10.439 | -18.721 | -2.157 |
| BMI (per 1 point increase) | -0.845  | -1.429             | -0.262             |
| NT-proBNP (per 100 points increase) | -0.063  | -0.107             | -0.020             |
| Depression           | -15.179 | -21.841            | -8.517             |
| **KCCQ-CS**          |         |                    |                    |
| Age (per 10 years increase) | -0.526  | -2.635             | 1.583              |
| Male                 | 10.185  | 4.749              | 15.621             |
| Previous HF          | -7.133  | -12.643            | -1.622             |
| Chronic obstructive pulmonary disease | -7.815  | -14.527           | -1.103             |
| BMI (per 1 point increase) | -1.047  | -1.527             | -0.567             |
| Systolic blood pressure (per 10 points increase) | 1.143    | 0.209              | 2.077              |
| NT-proBNP (per 100 points increase) | -0.058  | -0.094             | -0.022             |
| Depression           | -13.677 | -19.142            | -8.212             |
| **KCCQ-OS**          |         |                    |                    |
| Age (per 10 years increase) | 0.441   | -1.511             | 2.393              |
| Male                 | 7.167   | 2.183              | 12.151             |
| Previous HF          | -5.872  | -10.907            | -0.836             |
| Ischemic HF          | -6.009  | -10.904            | -1.115             |
| BMI (per 1 point increase) | -0.718  | -1.150             | -0.285             |
| Systolic blood pressure (per 10 points increase) | 1.034    | 0.184              | 1.884              |
| NT-proBNP (per 100 points increase) | -0.052  | -0.084             | -0.019             |
| Anxiety              | -7.463  | -12.945            | -1.981             |
| Depression           | -14.279 | -19.695            | -8.864             |

BMI, body mass index; CI, confidence interval; CS, clinical summary score; EQ-5D, EuroQuality-of-life 5 Dimensions; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic.
completed the questionnaires for reasons unknown or who may have not received the questionnaires from their caregivers. Anyway, the baseline characteristics of the responders and non-responders were largely comparable so the missing seems to be at random.

**Conclusions**

In conclusion, HF patients without comorbidity had better HRQoL and less depression than patients with comorbidity. Sex, previous HF, COPD, BMI, NT-proBNP levels, and presence of anxiety and depression were determinants of HRQoL in patients with comorbidity. In contrast, we have found hardly any demographic or clinical determinants of HRQoL in those without comorbidity. In clinical practice, in addition to aiming for improved survival, physicians may pay greater attention to improving HRQoL of HF patients both with and without comorbidity.

**Supplementary material**

Supplementary material is available at *European Journal of Cardiovascular Nursing.*

---

**Figure 1** Multivariable adjusted determinants of HRQoL in patients with and without comorbidity. Round symbols indicate results for patients with comorbidity, square symbols indicate results for patients without comorbidity. BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CS, clinical summary score; EQ-5D, EuroQuality-of-life 5 Dimensions; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OS, overall summary score; PL, physical limitation; SBP, systolic blood pressure; VAS, visual analogue scale.
Funding
This work received support within the framework of CTMM (Center for Translational Molecular Medicine), project TRIUMPH (grant 01C-103).

Conflict of interest: none declared.

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.

References
1. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuza M, Zannad F, Pitt B, O’Connor CM. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281–2293.
2. van Deursen VM, Damman K, van der Meer P, Wijkstra PJ, Luijckx GJ, van Beek A, van Veldhuisen DJ, Voors AA. Co-morbidities in heart failure. Heart Fail Rev 2014;19:163–172.
3. Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL. Van Veldhuisen DJ, Sandersen R. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. J Card Fail 2009;15:17–23.
4. Camin-Colet J, Anguita M, Formiga F, Almenar L, Crespo-Leiro MG, Manzano L, Muljic J, Chaves J, de Frutos E, Enjuanes C. Health-related quality of life of patients with chronic systolic heart failure in Spain: results of the VIDA-IC study. Rev Esp Cardiol (Engl Ed) 2016;69:256–271.
5. Juergen J, Schellberg D, Kramer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002;87:235–241.
6. Maitenbrot M, Versteeg H, Zijlstra W, Meine M, Sertorus JA, Pedersen SS. Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies. Eur J Heart Fail 2014;16:384–393.
7. Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 2013;15:1113–1121.
8. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016–1024.
9. Lawson CA, Solis-Trapala I, Dahlstrom U, Mams M, Jaarsma T, Kadam UT, Stromberg A. Comorbidity health pathways in heart failure patients: sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018;15:e1002540.
10. Fujita B, Lauten A, Goebel B, Franz M, Fritzenwanger M, Ferrari M, Figulla HR, Kuehle F, Jung C. Impact of diabetes mellitus on quality of life in patients with congestive heart failure. Qual Life Res 2012;21:1171–1176.
11. Kraai IH, Luttik MLA, Johansson P, De Jong RM, Van Veldhuisen DJ, Hillege HL, Jaarsma T. Health-related quality of life and anemia in hospitalized patients with heart failure. Int J Cardiol 2012;161:151–155.
12. Nesbitt T, Doctorvaladan S, Southard JA, Singh S, Felkate A, Marie K, Moser DK, Felter MM, Robinson S, Wilson MD, Cooper L, Drapac K. Correlates of quality of life in rural patients with heart failure. Circ Heart Fail 2014;7:882–887.
13. van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, Westenbrink BD, Brunner-la Rocca HP, van Miltenburg AJM, Boersma E, Hillege HL, Akkerhuis KM. TRIUMPH Investigators. Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol 2017;70:2378–2388.
14. van Vark LC, Lesman-Leegte I, Baart SJ, et al. Prognostic value of serial galectin-3 measurements in patients with acute heart failure. J Am Heart Assoc 2017;6.
15. Goodyear MD, Kriésa-Jenic K, Lemmens T. The Declaration of Helsinki. BMJ 2007;335:624–625.
16. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;13:1787–1847.
17. Green CP, Porter CB, Bresnahan DR, Speratus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245–1255.
18. EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
19. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
20. Zigndom AS, Snath RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
21. Ambrosy AP, Hernandez AF, Armstrong PW, Butler J, Dunning A, Ezekowitz J, Felker GM, Greene SJ, Kaul P, McMurray JJ, Metra M, O’Connor CM, Reed SD, Schulte PJ, Starling RC, Tang WH, Voors AA, Mentz RJ. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail 2016;18:306–313.
22. Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; for the CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83–91.
23. Kravitz RL, Grant J. Coping and health-related quality of life in individuals with heart failure: an integrative review. Heart Lung 2013;42:183–194.
24. Iqbal J, Francis L, Reid J, Murray S, Dervin M. Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail 2010;12:1002–1008.
25. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
26. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Schild EF, Kraus VE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piatti IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439–1450.
27. Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care 2014;8:233–237.
28. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;CD003331.
29. Neuback L, Freedman SB, Clark AM, Briffa T, Bauman A, Reardon J. Participating in cardiac rehabilitation: a systematic review and meta-synthesis of qualitative data. Eur J Prev Cardiol 2012;19:494–503.
30. Bjarnason-Wehrens B, McGee H, Zwissler A-D, Papolo MF, Benzer W, Schmid JP, Dendle P, Pogosova Ni-GV, Zidrengaia D, Niebauer J, Mendes M. Cardiac Rehabilitation Section European Association of Cardiovascular Prevention and Rehabilitation. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. J Cardiovasc Prev Rehabil 2010;17:410–418.